By Daniella Parra
Agendia said its FLEX Study has enrolled over 17,000 early-stage breast cancer patients from diverse ethnic and racial backgrounds, aiming to address racial and ethnic disparities in breast cancer treatment.
The study is a large-scale, real-world evidence, observational breast cancer study designed to gather comprehensive genomic and clinical data, they said.
“Agendia, in partnership with clinicians and researchers from around the world, is spearheading the discovery and compilation of valuable data that have the potential to impact how early breast cancer patients receive treatment based on their specific biologic profile,” said Joyce O’Shaughnessy, MD, National Principal Investigator of the FLEX Study.
Contact:
Editor@executives-edge.com
